Drs Cheryl Lee and Andrea Apolo discuss combination systemic therapy strategies for urothelial carcinoma, including dose de-escalation for toxicity reduction, and how ctDNA efforts are paving the way for precision medicine with the promise of biomarkers.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987107). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Systemic Treatment for Advanced Urothelial Cancer: An Update on Recent Clinical Trials and Current Treatment Options https://pubmed.ncbi.nlm.nih.gov/32668516/

PD-L1 Assessment in Urothelial Carcinoma: A Practical Approach https://pubmed.ncbi.nlm.nih.gov/31930091/

Immune Checkpoint Inhibitors in Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/35621637/

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/33224141/

BCG-Unresponsive High-Grade Non-muscle Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://pubmed.ncbi.nlm.nih.gov/33772322/